

Press release, September 5, 2007

Per Carendi new CEO of SLS Venture

The board of the Scandinavian venture capital group SLS Venture has appointed Per Carendi new chief executive officer. He has many years' of experience from taking an active part in the work of the boards of several companies, lately focusing on the life science sector. Per is presently chairman of the board of SLS Venture's portfolio company Doxa.

"Many of SLS Venture's portfolio companies are facing commercialisation, strategic acquisitions, mergers or sales. Per has with great success taken part in and carried out commercialisations as well as strategic company transactions – most recently the Entific trade sale and the merger between A+ Science and Vita Nova Ventures – and has, consequently, exactly the competence and the experience we need at this stage in order to enhance the values of our portfolio", says Lars Ingelmark, Chairman of the Board, SLS Venture.

Per Carendi takes up his post on October 1st. He is preceeding Jonas Frick who, after 4,5 years, has decided to leave the company.

For further information, please contact:

Lars Ingelmark, Chairman of the Board, SLS Venture, tel +46 708 74 10 35,
e-mail: lars.ingelmark@APFOND6.se

SLS Venture is one of the leading venture capital companies focused on life science in Scandinavia. With a wide experience from research, development and company management within the biotech and pharmaceutical industry as well as a broad network, SLS Venture is an active owner of its portfolio companies. The equity in charge amounts to USD 325 M. The portfolio includes Biolipox AB, Doxa AB, Sophion Bioscience A/S, Aerocrine AB and NeuroNova AB.